Report Company Directory
- Phase Ia progressing successfully; new COVID strain by proactiveinvestors
- COVID-19 therapy trial underway, RSV trial to follow by proactiveinvestors
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City by GlobeNewsWire
- DGAP-News: NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage by EQS Group AG
- DGAP-News: NanoViricides, Inc.: Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan by EQS Group AG
- DGAP-News: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress by EQS Group AG
- DGAP-News: NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 by EQS Group AG
- DGAP-News: NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock by EQS Group AG
- DGAP-News: NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock by EQS Group AG
- DGAP-News: NanoViricides Announces Addition to Russell Microcap(R) Index by EQS Group AG